1. Background {#sec117470}
=============

Coronary Artery Diseases (CADs) are the main causes of death in the world. It has been reported that the CADs have been the most leading cause of death in 2012 ([@A29933R1]). In the United States, one of every six death in 2010 has been due to the CADs ([@A29933R2]). In developing countries, cardiovascular disease and related life style factors are the main reason of morbidity and mortality ([@A29933R3], [@A29933R4]). Similarly, in Iran, cardiovascular diseases accounted for 45% of causes of death ([@A29933R5]).

Life-threatening and devastating nature of CADs is a leading factor of mental health problems in patients ([@A29933R6], [@A29933R7]). In this respect, anxiety and depression are common issues of patients during the process of heart diseases ([@A29933R8], [@A29933R9]). Luttik et al. ([@A29933R10]) in a study with 217 patients with CADs reported that 26% and 42% of the patients showed depression and anxiety symptoms. In Ghaleiha et al.'s study ([@A29933R11]), the prevalence of anxiety and depression in 360 Iranian hospitalized patients with heart diseases were reported to be 47.5% and 66.6%, respectively. Similarly in another Iranian study, Beyraghi et al. ([@A29933R12]) reported that 90% and 72% of patients with heart diseases had symptoms of anxiety and depression, respectively.

Anxiety and depression in patients with heart diseases are associated with a poor prognosis, and higher morbidity and mortality ([@A29933R13]-[@A29933R15]). In fact, they affect the physical and psychological well-being of patients and reduce their survival and quality of life ([@A29933R16], [@A29933R17]).

Uncertainty in life situation has been mentioned as one reason of anxiety and depression in patients with the CADs ([@A29933R18]). Moreover, encountering with life-threatening and stressful conditions, enhance patients' anxiety symptoms and establish the feelings of helplessness, self-reproaches, weakness, grave fear and depression in such patients ([@A29933R18], [@A29933R19]). In this regard, knowledge improvement and educational support about the nature of cardiac symptoms have been stated to help patients accept early treatment, and reduce the risk of progression of the CADs ([@A29933R20]). Rahmati Najarkolaei et al. ([@A29933R21]) suggested improvise educational interventions based on CAD risk factors are the most important and effective strategies in decreasing the morbidity and mortality of high-risk populations. In fact, those patients who do not recognize their cardiac diagnosis might have a higher level of anxiety in comparison to those patients who know about their disease ([@A29933R10]). Thus, providing information to patients with the CADs is an important nursing intervention ([@A29933R22]).

One of the proposed tools to improve patients outcomes is clinical pathway (CP) that has been introduced since1985 ([@A29933R23]). The CP is a multidisciplinary outline designed to guide how patients can be cared for, when and by whom ([@A29933R24]). The CP can define the course of treatment in detailed steps in a plan or inventory of actions ([@A29933R25]). It has some advantages such as reducing the variation of care, improving the knowledge of patient and his/her family, increasing understanding of the patient of therapeutic procedures ([@A29933R23]). It not only can significantly improve the quality of care and patient's outcomes ([@A29933R26]-[@A29933R29]), but also has some benefits such as providing routine day-to-day care plans and detailed information on the treatment process ([@A29933R30]). Also, the CPs can enhance the patients' knowledge about treatment process ([@A29933R31]).

Although the CPs are used as a tool to improve the quality of care in health care management that usually used by health care staff ([@A29933R23]); however, no previous study is available to investigate the effectiveness of these tools when using by patients.

2. Objectives {#sec117471}
=============

Therefore, this study was conducted to explore the effectiveness of a patient-focused clinical pathway on anxiety, depression and satisfaction of patients with CAD.

3. Patients and Methods {#sec117478}
=======================

3.1. Design {#sec117472}
-----------

This quasi-experimental study was performed on 138 patients over the age of 30 years old who were admitted to a coronary care unit (CCU) of a referral teaching hospital (Fatemiyeh's Hospital) affiliated to Semnan University of Medical Sciences in Semnan, Iran. The hospital was governmental with 4 medical wards, CCU, medical intensive care unit (ICU) and hemodialysis unit.

3.2. Participants {#sec117473}
-----------------

The inclusion criteria for patients who admitted to CCU were CAD and having at least literacy to read the clinical pathway. Also, patients with sudden life-threatening conditions, known psychiatric disorders such as chronic anxiety or depression and experiencing the complicated myocardial infarction were excluded. From 152 patients who were admitted with CAD in CCU, 138 patients were enrolled in this study and 14 patients excluded because of complications. The participants were recruited using a convenience sampling method. Then, every patient who had inclusion criteria was recruited and allocated into two groups: CP and Routine (RUT). In order to prevent contamination of the participants, according to environment of the CCU, the total numbers of beds in the CCU (10 beds) were randomly divided into two halves and apart from each other as: 5-beds were considered for the CP group and 5-beds for the RUT group ([Figure 1](#fig22429){ref-type="fig"}). In this regard, the patients in each group were chosen separately and had no communication with each other throughout the study process.

![Research Steps](ircmj-17-09-29933-i001){#fig22429}

3.3. Intervention {#sec117474}
-----------------

At first, according to therapeutic and caring protocols of the CCU, a CP was developed with the aim of informing patients with CADs of their treatment process. A multidisciplinary team consisting of a cardiologist, a head nurse of CCU, a dietician, a laboratory and a radiology technician involved in designing this clinical pathway. The CP was designed in such a way that the patients with minimum of reading literacy would be able to read and follow its contents. They could follow their treatment and caring process using the CP and ask questions about caring procedures.

The pathway was consisted of main daily medical and nursing interventions implemented in the CCU for patient with CAD. The CP focused on:

1.  Patient's activities of daily living (ADL)

2.  Diagnostic and laboratory tests

3.  Pharmacologic treatments

4.  Nutritional plan

5.  Monitoring and caring procedures

6.  Medical consultation

[Table 1](#tbl30253){ref-type="table"} depicts a summary of the contents of the CP. In the intervention group, the responsible nurse for each patient would record the interventions conducted for the patients. Patients could read their related interventions, as they would be informed of expected actions and protocols of their care process. In the control group, the patients were treated according to routine care protocols of the CCU.

###### Summarized Clinical Pathway for Patients With Coronary Artery Diseases (CADs) ^[a](#fn30427){ref-type="table-fn"}^

  Medical and Nursing Interventions                                                         Days of Hospitalization in Coronary Care Unit, CCU                                                                                                                                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------
  **Activity status**                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                            Complete bed rest (CBR)                                                         CBR                                                       CBR (if Troponin test was positive);                                                                                                                     CBR (if suddenly occurs hypotension);                         CBR (if suddenly occurs hypotension),
                                                                                                                                                                                                                                      CBR (if there is dysrhythmia;                                                                                                                                                                                          
                                                                                                                                                                                                                                      relative bed rest (RBR) if Troponin test was negative and there is no dysrhythmia (activity is limited to around the bed and with permission of nurse)   RBR (activity is very limited and with permission of nurse)   RBR (activity is limited and with permission of nurse)
  **Laboratory tests**                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                            Troponin                                                                        Troponin                                                                                                                                                                                                                                                                         
                                                                                            Complete blood count                                                                                                                                                                                                                                                                                                                                             
                                                                                            Blood sugar                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                            Fasting blood sugar (FBS)                                                                                                                                                                                                                                                        
                                                                                                                                                                            Cholesterol                                                                                                                                                                                                                                                                      
                                                                                                                                                                            Triglyceride                                                                                                                                                                                                                                                                     
                                                                                            Serum sodium and potassium                                                                                                                                                                                                                                                                                                                                       
                                                                                            PT & PTT                                                                        PT & PTT                                                  PT & PTT                                                                                                                                                 PT & PTT                                                      PT & PTT
                                                                                            Creatinine                                                                                                                                                                                                                                                                                                                                                       
                                                                                            Other                                                                           Other                                                     Other                                                                                                                                                    Other                                                         Other
  **Medications**                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Oral                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                            Aspirine                                                                        Aspirine                                                  Aspirine                                                                                                                                                 Aspirine                                                      Aspirine
                                                                                            Tranqulizers                                                                    Tranqulizers                                              Tranqulizers                                                                                                                                             Tranqulizers                                                  Tranqulizers
                                                                                            Captopril                                                                       Captopril                                                 Captopril                                                                                                                                                Captopril                                                     Captopril
                                                                                            Ranitidine                                                                      Ranitidine                                                Ranitidine                                                                                                                                               Ranitidine                                                    Ranitidine
                                                                                            Metoral                                                                         Metoral                                                   Metoral                                                                                                                                                  Metoral                                                       Metoral
                                                                                            Laxatives                                                                       Laxatives                                                 Laxatives                                                                                                                                                Laxatives                                                     Laxatives
                                                                                            Atrostatine                                                                     Atrostatine                                               Atrostatine                                                                                                                                              Atrostatine                                                   Atrostatine
                                                                                                                                                                            Nitrocantine (if Troponin test was negative)              Nitrocantine (if Troponin test was negative)                                                                                                             Nitrocantine (if troponin test was negative)                  Nitrocantine (if troponin test was negative)
  Intravenous                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                            Nitroglycerine                                                                  Nitroglycerine (if troponin test was positive)                                                                                                                                                                                                                                   
                                                                                            Morphin or Petedine                                                             Morphin or Petedine (if chest pain is present)                                                                                                                                                                                                                                   
                                                                                            Heparin or Anoxaprine                                                           Heparin or Anoxaprine                                     Heparin or Anoxaprine                                                                                                                                    Heparin or Anoxaprine                                         Heparin or Anoxaprine
                                                                                            Stereptokinase if physician recommended                                                                                                                                                                                                                                                                                                                          
                                                                                            Others                                                                          Others                                                    Others                                                                                                                                                   Others                                                        Others
  **Dietary recommendations**                                                               ;;                                                                              ;                                                         ;                                                                                                                                                        ;                                                             ;
                                                                                            Low salt and fat (white meat: chicken or fish)                                  Low salt and fat (preferably white meat)                  Low salt and fat (preferably white meat)                                                                                                                 Low salt and fat (preferably white meat)                      Low salt and fat (preferably white meat)
                                                                                            NPO for 6 hours if Stereptokinase administered                                  Low salt and fat and diabetic (if patient had diabetes)   Low salt and fat and diabetic (if patient had diabetes)                                                                                                  Low salt and fat and diabetic (if patient had diabetes)       Low salt and fat and diabetic (if patient had diabetes)
                                                                                            NPO for 24 hours if there is nausea and vomiting                                                                                                                                                                                                                                                                                                                 
  **Vital signs monitoring**                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                            Vital signs monitoring per 6 hours (especially blood pressure and heart rate)   Vital signs monitoring per 6 hours                        Vital signs monitoring per 6 hours                                                                                                                       Vital signs monitoring per 6 hours                            Vital signs monitoring per 6 hours
                                                                                                                                                                            Blood pressure monitoring if hypotension is present       Blood pressure monitoring if hypotension is present                                                                                                      Blood pressure monitoring if hypotension is present           Blood pressure monitoring if hypotension is present
  **Medical counseling** ^**[b](#fn30428){ref-type="table-fn"}**^                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                            Endocrinology (diabetes)                                                        Endocrinology (diabetes)                                  Endocrinology (diabetes)                                                                                                                                 Endocrinology (diabetes)                                      Endocrinology (diabetes)
                                                                                            Renal                                                                           Renal                                                     Renal                                                                                                                                                    Renal                                                         Renal
                                                                                            Gastrointestinal                                                                Gastrointestinal                                          Gastrointestinal                                                                                                                                         Gastrointestinal                                              Gastrointestinal
                                                                                            Respiratory                                                                     Respiratory                                               Respiratory                                                                                                                                              Respiratory                                                   Respiratory
                                                                                            Others                                                                          Others                                                    Others                                                                                                                                                   Others                                                        Others
  **Complementary practice**                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                            Electrocardiogram (EKG) before and after Sterptokinase                          Daily ECG before physician visiting                       Daily ECG before physician visiting                                                                                                                      Daily EKG before physician visiting                           Daily ECG before physician visiting
                                                                                            Oxygenation by mask or nasal cannula                                            □ ECG if there is chest pain                              ECG if there is chest pain                                                                                                                               ECG if there is chest pain                                    ECG if there is chest pain
  **Patient's education and discharge planning** ^**[c](#fn30429){ref-type="table-fn"}**^                                                                                                                                                                                                                                                                                                                                                                    
                                                                                            1\. Administration of medications at home                                       1\. Administration of medications at home                 1\. Administration of medications at home                                                                                                                1\. Administration of medications at home                     1\. Administration of medications at home
                                                                                            2\. Dietary recommendations                                                     2\. Dietary recommendations                               2\. Dietary recommendations                                                                                                                              2\. Dietary recommendations                                   2\. Dietary recommendations
                                                                                            3\. Follow-up care and time of re-visiting by physician                         3\. Follow-up care and time of re-visiting by physician   3\. Follow-up care and time of re-visiting by physician                                                                                                  3\. Follow-up care and time of re-visiting by physician       3\. Follow-up care and time of re-visiting by physician
                                                                                            4\. Type and level of activities                                                4\. Type and level of activities                          4\. Type and level of activities                                                                                                                         4\. Type and level of activities                              4\. Type and level of activities
                                                                                            5\. Stress management actions                                                   5\. Stress management actions                             5\. Stress management actions                                                                                                                            5\. Stress management actions                                 5\. Stress management actions
                                                                                            6\. Avoiding from smoking (if patient is smoker)                                6\. Avoiding from smoking (if patient is smoker)          6\. Avoiding from smoking (if patient is smoker)                                                                                                         6\. Avoiding from smoking (if patient is smoker)              6\. Avoiding from smoking (if patient is smoker)
                                                                                            7\. Insulin injection (if patient has diabetic)                                 7\. Insulin injection (if patient has diabetic)           7\. Insulin injection (if patient has diabetic)                                                                                                          7\. Insulin injection (if patient has diabetic)               7\. Insulin injection (if patient has diabetic)

^a^ This table was summarized form of CP and was modified for presentation to this manuscript.

^b^ According to heart physician recommendation.

^c^ Patient education is focused on patients' questions about treatment process and side effects of medications. Discharge planning is begin gradually and is focused on mentioned items.

3.4. Data Collection {#sec117475}
--------------------

The levels of patient's anxiety, depression and satisfaction were measured as the study outcomes. To prevent measurement bias, a non-participant in this study collected data. Anxiety and depression in patients were measured in two stages: after admission to the CCU (pretest) and at the time of discharge from CCU (posttest). Patient's satisfaction was measured only after discharge from CCU (posttest).

In the both groups, after admission to the CCU and becoming ensure of the stabilization of patients' status, the hospital anxiety and depression scale (HADS) was completed for each patient ([@A29933R32]). Again, at the time of discharge from the CCU, the level of anxiety and depression of the patients were remeasured using the HADS. The HADS was a Likert scale composed of 14 items (7 for anxiety and 7 for depression) to which patients responded through a 4-point scale (from 0 to 3). The scores of anxiety and depression were calculated separately by sum of the scores in the domain between 0 and 21.

The HADS is a useful and valid instrument to assess patients' anxiety and depression in clinical settings in three categories: 0 - 7 (normal), 8 - 10 (borderline) and 11 - 21 (abnormal). The validity and reliability of HADS was confirmed by multiple studies ([@A29933R15], [@A29933R32]). In this study, the Iranian version of the HADS ([@A29933R33]) was used. In addition, the reliability of this scale using the Cronbach's alpha coefficient was estimated to be 0.89.

The patients' satisfaction was measured using the Hinshaw and Atwood's Patients Satisfaction Instrument (PSI) that its validity and reliability was confirmed by several studies ([@A29933R34], [@A29933R35]). The PSI was comprised of 25 items. The dimensions of patient's satisfaction were technical-professional care (7 items), trust (11 items), and patient education (7 items). The instrument measured the patients' view about care using 5-point Likert scale in a range of strongly disagree (score 1) to strongly agree (score 5). In this study, the Persian version of the PSI ([@A29933R36]) was completed by patients after discharging from the CCU. Also, the reliability of this scale using the Cronbach's alpha coefficient was reported to be 0.84.

3.5. Sample Size and Data Analysis {#sec117476}
----------------------------------

Since there was no similar study exactly, a pilot study was conducted to determine the number of sample size. The mean and standard deviation were calculated for anxiety difference scores (in the CP group: 0.65 ± 1.21 and the RUT group: -0.27 ± 1.63), depression difference scores (in the CP group: 0.74 ± 1.67 and the RUT group: -0.06 ± 1.47) and patient's satisfaction scores (in the CP group: 992.5 ± 9.7 and in the RUT group: 86 ± 12). Then according to acquired parameters with a two-tailed α of 0.05 and a (1-β) of 0.80, for a comparison of two independent proportions, it was estimated to be 69 patients per each group.

Finally, data analysis was performed using statistical tests such as Kolmogorov-Smirnov, pair and independent sample T-test, Mann-Whitney, chi-square and general linear model: repeated measures analysis at 5% significance level with SPSS version.18 software for Windows.

3.6. Ethical Consideration {#sec117477}
--------------------------

The study was approved by the research ethics boards of Semnan University of Medical Sciences, Semnan, Iran and it was registered in Iranian registry of clinical trials (IRCT ID: IRCT201202235134N5). The objectives of the study were explained in detail to each participant. Information with regard to the voluntary nature of the participation, their right to privacy and anonymity as well as right to withdraw from the study at any time without any penalty were stated to the patients. Finally, the participants signed an informed consent form.

4. Results {#sec117482}
==========

4.1. Demographic Data {#sec117479}
---------------------

Most of the patients were male (67.4%). The mean age of the patients was 58.86 ± 10.81 years. Also, the age of 53.6% of the patients was less than 60 years. In terms of educational level, 50.7% of the subjects were less than high school, 35.5% had diploma and 13.8% were over diploma (associate, bachelor's and master's degrees). Fifty percent of them were hospitalized for the first time in the CCU. Also, 83.3% of patients were diagnosed with unstable angina and 16.7% suffered from myocardial infarction. It was shown that there was no significant difference between the intervention and control groups in terms of participants' characteristics such as gender, age, education level, times of hospitalization in the CCU and sort of the disease (P \> 0.05) ([Table 2](#tbl30254){ref-type="table"}).

###### Participant Characteristics in Two Groups of Study ^[a](#fn30430){ref-type="table-fn"},[b](#fn30431){ref-type="table-fn"}^

  Participant Characteristics                                CP Group    RUT Group   P Value ^[c](#fn30432){ref-type="table-fn"}^
  ---------------------------------------------------------- ----------- ----------- ----------------------------------------------
  **Gender**                                                                         0.204
  Male                                                       43 (62.3)   50 (72.5)   
  Female                                                     26 (37.8)   19 (27.5)   
  **Age, y**                                                                         0.116
  Below 60                                                   41 (29.7)   33 (23.9)   
  Above 60                                                   28 (20.3)   36 (26.1)   
  **Education level**                                                                0.167
  Cycle                                                      35 (25.4)   35 (25.4)   
  Diploma                                                    28 (20.3)   21 (15.2)   
  Over diploma (associate, bachelor's and master's degree)   6 (4.3)     13 (9.4)    
  **Times of hospitalization in CCU**                                                0.644
  First                                                      34 (24.6)   35 (25.4)   
  Second                                                     18 (13)     22 (15.9)   
  Third                                                      6 (4.3)     5 (3.6)     
  Fourth                                                     6 (4.3)     2 (1.4)     
  Fifth                                                      5 (3.6)     5 (3.6)     
  **Sort of disease**                                                                0.500
  Unstable angina                                            58 (42)     57 (41.3)   
  Myocardial infarction                                      11 (8)      12 (8.7)    

^a^ Abbreviations: CP, clinical pathway; and RUT, routine.

^b^ Data are presented as No. (%).

^c^ Chi-square test.

4.2. Anxiety and Depression Levels {#sec117480}
----------------------------------

At the admission time, in the CP group, 8.0% and 3.6% of the patients had borderline and abnormal anxiety levels, respectively (5.04 ± 3.49). While in time of discharge from CCU, 8.7% and 0.7% of the cases were in borderline and abnormal anxiety levels, respectively (4.52 ± 3.25). In the RUT group, the range of anxiety among patients was 9.4% (borderline) and 3.6% (abnormal) (4.96 ± 3.45) at the admission time, whilst this range was 8.7% (borderline) and 3.6% (abnormal) in time of discharge from CCU (5.13 ± 3.39).

In term of depression, at the admission time in the CP group 10.1% and 5.8% of the cases had borderline and abnormal depression levels, respectively (5.25 ± 3.95). However, in time of discharge from CCU, range of depression among the CP group patients was 10.1% (borderline) and 0.7% (abnormal) (4.49 ± 3.51). In the RUT group, 10.9% and 2.9% of the cases had borderline and abnormal depression levels, respectively at the admission time (5.43 ± 3.22). While in time of discharge from CCU, 10.1% and 3.6% of the cases were in borderline and abnormal anxiety levels, respectively (5.43 ± 3.09).

4.3. Comparing Outcomes {#sec117481}
-----------------------

To compare the anxiety and depression between the CP and RUT groups, the mean of difference between pretest scores with posttest scores in each of them (pretest-posttest) was measured between the groups. In terms of anxiety, this difference was 0.52 ± 1.39 and -0.17 ± 1.69 in the CP and RUT groups, respectively. There was a significant difference between two groups (P = 0.009), as anxiety in the CP group was lower compared to the RUT group ([Table 3](#tbl30255){ref-type="table"}). In terms of depression, this difference was 0.75 ± 2.05 and 0.00 ± 1.08 in the CP and RUT groups, respectively. There were a significant difference between the two groups (P = 0.024), as depression in the CP group was lower compared to the RUT group ([Table 4](#tbl30256){ref-type="table"}).

###### Comparing the Anxiety Scores Between Two Groups of the Study ^[a](#fn30433){ref-type="table-fn"},[b](#fn30434){ref-type="table-fn"}^

  Anxiety Scores                           CP Group      RUT Group      P Value ^[c](#fn30435){ref-type="table-fn"}^
  ---------------------------------------- ------------- -------------- ----------------------------------------------
  **Pretest**                              5.04 ± 3.49   4.96 ± 3.45    0.883
  **Posttest**                             4.52 ± 3.25   5.13 ± 3.39    0.284
  **Difference of pretest and posttest**   0.52 ± 1.36   -0.17 ± 1.69   0.009

^a^ Abbreviations: CP, clinical pathway; and RUT, routine.

^b^ Data are presented as mean ± SD.

^c^ Independent t-test.

###### Comparing the Depression Scores Between Two Groups of the Study ^[a](#fn30436){ref-type="table-fn"},[b](#fn30437){ref-type="table-fn"}^

  Depression Scores                        CP Group      RUT Group     P Value ^[c](#fn30438){ref-type="table-fn"}^
  ---------------------------------------- ------------- ------------- ----------------------------------------------
  **Pretest**                              5.25 ± 3.95   5.43 ± 3.22   0.760
  **Posttest**                             4.49 ± 3.51   5.43 ± 3.09   0.097
  **Difference of pretest and posttest**   0.75 ± 2.05   0.00 ± 1.83   0.024

^a^ Abbreviations: CP, clinical pathway; and RUT, routine.

^b^ Data are presented as mean ± SD.

^c^ Independent t-test.

Also, the repeated measure analysis was used to evaluate the interaction between the groups and repeated in terms of anxiety and depression. In anxiety, the interaction between group and repeated was significant (F (1,136) = 7.12, P = 0.009). This means that the score of anxiety before and after intervention (i.e. in two measurements) was affiliated to the group, which is also seen in [Figure 2](#fig22430){ref-type="fig"}. Also, the results showed that the mean anxiety score difference before and after the intervention of two groups (0.52 in CP and -0.17 in RUT) had a significant difference (P = 0.009).

The patient's satisfaction in the CP group (3.69 ± 0.39) was significantly higher compared to the RUT group (3.45 ± 0.47) in terms of total scores (P = 0.002). Also, technical-professional dimension in the CP group (3.80 ± 0.53) was significantly higher (P = 0.002) compared to the RUT group (3.51 ± 0.52). Educational dimension was higher (P = 0.019) in the CP group (3.70 ± 0.56) compared to the RUT group (3.45 ± 0.64). In addition, trust dimension had achieved significantly more points in the CP group (3.61 ± 0.36) compared to the RUT group (3.40 ± 0.48) (P = 0.006) ([Table 5](#tbl30257){ref-type="table"}).

###### Comparing the Patients' Satisfaction Between Two Groups of the Study ^[a](#fn30439){ref-type="table-fn"}^

  Dimensions of PSI            CP Group      RUT Group   P Value                               
  ---------------------------- ------------- ----------- --------- ------------- ------ ------ --------------------------------------------
  **Technical-professional**   3.80 ± 0.53   3.85        0.71      3.51 ± 0.52   3.57   0.64   0.002 ^[b](#fn30440){ref-type="table-fn"}^
  **Educational**              3.70 ± 0.56   3.71 ±      0.71      3.45 ± 0.64   3.57   0.86   0.019 ^[c](#fn30441){ref-type="table-fn"}^
  **Trust**                    3.61 ± 0.36   3.63 ±      0.36      3.40 ± 0.48   3.45   0.82   0.006 ^[b](#fn30440){ref-type="table-fn"}^
  **Total scores of PSI**      3.69 ± 0.39   3.72 ±      0.40      3.45 ± 0.47   3.48   0.66   0.002 ^[b](#fn30440){ref-type="table-fn"}^

^a^ Abbreviations: CP, clinical pathway; IQR, interquartile range; and RUT, routine.

^b^ Independent t-test.

^c^ Mann-Whitney test.

![Mean of Anxiety According to the Clinical Pathway and Control Groups in Admission to the (Trial 1) and Time of Discharge From Coronary Care Unit (Trial 2)](ircmj-17-09-29933-i002){#fig22430}

In depression, the interaction between group and repeated was significant (F (1,136) = 5.20, P = 0.024). This means that the score of anxiety before and after intervention (i.e. in two measurements) was affiliated to the group, which is also seen in [Figure 3](#fig22431){ref-type="fig"}. Also, the results showed that the mean anxiety score difference before and after the intervention of two groups (0.75 in CP and 0.00 in RUT) had a significant difference (P = 0.024).

![Mean of Depression According to Clinical Pathway and Control Groups in Admission to the (Trial 1) and Time of Discharge From Coronary Care Unit (Trial 2)](ircmj-17-09-29933-i003){#fig22431}

5. Discussion {#sec117483}
=============

Patients with the CADs encounter with life-threatening conditions. They may experience some psychological problems such as anxiety and depression. Therefore, the management of these problems is important to enhance the patients' health status in the CCU. This study was performed to determine the effect of a patient-focused clinical pathway on the anxiety, depression and patient's satisfaction.

In this study, the prevalence rates of anxiety and depression in total of patients were 7.2% and 8.7%, respectively. In Beyraghi et al. study ([@A29933R12]), 90% and 70% of the patients in the CCU were shown symptoms of anxiety and depression, respectively. In DiGiacomo et al.'s study ([@A29933R37]), 15.8% and 10.3% of women following acute coronary syndrome had extremely severe anxiety and depression, respectively. Moreover, Arab et al. ([@A29933R38]) measured the anxiety and depression of patients after 48 hours of admission in the CCU. Their results showed that the mean scores of anxiety and depression were 10.12 ± 3.49 and 10.10 ± 2.69, respectively. A significant point in this study is a low level of anxiety and depression in comparison to other studies. In this study, anxiety and depression had been measured after stabilization of patients' status and chest pain relief, that maybe these have been the reason of lower incidence of anxiety and depression in this study.

In this study, the CP helped to reduce the level of anxiety and depression in patients with CADs. Similar to this study, Tastan et al.'s ([@A29933R30]) study showed that CP reduced the anxiety scores of patients with breast cancer undergoing breast surgery. Also, in Sulch et al.'s study ([@A29933R39]), the care pathway similar to the conventional care decreased the patients' anxiety and depression of patients. Contrary to this study, El Baz et al. ([@A29933R40]) not only did not observe any difference between the study groups in terms of depression, but also, found that anxiety scores in the conventional-care group were lower that the CP group, that supports this notion that educating the patients may increase patients' anxiety or depression ([@A29933R41], [@A29933R42]). In our study it seems that the CP was enhanced the patient knowledge of the disease process; so, they already had prepared to face with unexpected actions or interventions. Also, in this study participants' characteristics were similar between the groups and there was no significant difference among patients. Whilst, El Baz et al. ([@A29933R40]) concluded that the confounding personal characteristics such as ethnicity, co-morbidity and personality traits must be taken into consideration in designing CP.

Clinical pathway enhanced the patients' satisfaction scores. The effect of CP on patient's satisfaction has been considered in other studies. Graeber et al. ([@A29933R43]) concluded that introduction of CP in general surgery patients was improved their satisfaction that was due to a reduced length of hospital stay, number of laboratory tests, number of consultations, and number of imaging procedures. However, in another study with the aim of comparing quality of life, satisfaction and functional outcomes in patients with fractured neck of femur between the standard care and clinical pathway, the results showed that there was no significant difference between the groups on clinical and functional outcome, quality of life and satisfaction ([@A29933R44]). In this study, perhaps reading of CP and acquiring awareness to treatment process had been leading to reduce the patients' concerns about interventions and treatment modes. Therefore, because they could follow their status on CP, they feel more satisfaction.

Most of the CPs were developed for management and quality improvement purposes and the main audience of them has been health-care personnel. However, in this study for the first time a patient-centered CP was designed for patients with the CADs. Although in this study, the patient-centered CP had positive effects on patients' anxiety, depression and satisfaction, but there were some limitations. In this study, although we had tried the patients unaware of each other, it seems that if this study was performed in multiple centers simultaneously, we could get complete results about efficacy of CP. Also, in this study, we cannot control the patient-physician communication. Since sometimes a trustful sense was formed between the physician and patient, this may influence the patient's anxiety. So, further studies are recommended in this area especially in other clinical settings.

According to the positive effects of CP on patients with CADs, it can be considered as a useful, safe and simple instrument for the improvement of patients' outcomes. Thus, the findings of this study can provide a new insight in patient care for clinical nurses. Further studies are suggested to investigate the efficacy of CP on other outcomes such as physiological indices and the quality of life in patients with the CADs.
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